DENVER & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its third oncology product candidate – an anaplastic lymphoma kinase (ALK) inhibitor discovered by ARIAD scientists – regulates multiple cancer pathways and is active in preclinical models of lung cancer, lymphoma and neuroblastoma. Preclinical data on ARIAD’s ALK inhibitor program are being presented today at the annual meeting of the American Association for Cancer Research (AACR) in Denver, Colorado.
